IQ-AI
Ltd
("IQ-AI" or the
"Company")
Imaging Biometrics and Prism
Clinical Imaging Secure First Installation
The combined technologies will
enhance neurosurgical planning and treatment
strategies
Imaging Biometrics (IB), a wholly
owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce
the successful first installation of its bundled technologies in
partnership with Prism Clinical Imaging, Inc. (Prism),
at a major Southeastern US health system. Prism,
recognized for its expertise in brain mapping software and
applications, and IB, a leading provider of quantitative imaging
solutions, have collaborated to deliver advanced tools that support
the diagnosis of brain diseases and improve treatment planning.
This marks the first installation under the partnership between
Prism and IB. The integrated technologies combine brain mapping and
analysis tools for clinical use in diagnosing brain disease and
guiding treatment.
The comprehensive suite of tools
offered by IB and Prism help clinicians treat brain tumor patients
by identifying structures to avoid when navigating to a tumor site
(Prism) and, once there, distinguishing
between aggressive tumor and non-tumor tissue (IB) to aid biopsy
and tumor resection planning. By providing detailed images of brain
activity and tumor physiology, the combined technologies allow
neurosurgeons to plan the safest and optimal surgical approach
while preserving functions like speech, movement, and sight. The
goal is to keep post-operative defects to a minimum and maximize
overall prognosis.
Functional magnetic resonance imaging
(fMRI) is experiencing growth driven by the increasing prevalence
of neurological disorders and the rising demand of diagnostic
tools. The advanced technologies offered by Prism and IB are
cutting-edge solutions for healthcare providers which can enhance
patient care and clinical outcomes.
--ENDS--
The Directors of the Company
accept responsibility for the contents of this
announcement.
For further information, please
contact:
IQ-AI Ltd
Trevor Brown/Dr Musella/Brett
Skelly/Michael Schmainda
Tel: 020 7469 0930
Peterhouse Capital
Limited (Financial Adviser and Broker)
Tel: 020 7220 9797
About Imaging Biometrics®, LLC:
IB is a wholly-owned subsidiary of IQ-AI Limited,
(LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians
diagnose and treat patients more efficiently and effectively. For
more information about Imaging Biometrics, visit the company's
website at www.imagingbiometrics.com. Follow IB on Twitter,
@IQAI_IB.
About Prism Clinical Imaging®,
Inc: Prism provides clinicians with imaging tools to
diagnose and plan treatment for brain disorders including tumors,
epilepsy, and other neurological disorders. Deployment options
range from on-premises to cloud-based. Please visit
www.prismclinical.com for further information. Follow Prism on
LinkedIn and Twitter, @PrismClinical.
